Long-term allogeneic islet graft survival in prevascularized subcutaneous sites without immunosuppressive treatment

American Journal of Transplantation

Volumn 14, Issue 7, 2014, Pages 1533-1542

  Luan, N M ^a   Iwata, H ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Allotransplantation; diabetes type 1; islet; neovascularization; subcutaneous

Indexed keywords

AGAROSE; FIBROBLAST GROWTH FACTOR 2; FLUORESCEIN ISOTHIOCYANATE; GLUCOSE; HEMOGLOBIN; HEPARIN; INSULIN; STREPTOZOCIN; GLUCOSE BLOOD LEVEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CAPILLARY; CELL ISOLATION; CELL STRUCTURE; CONTROLLED STUDY; DIABETES MELLITUS; FOLLOW UP; FUNCTIONAL ASSESSMENT; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GRAFT SURVIVAL; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; INSULIN BLOOD LEVEL; LONG TERM SURVIVAL; LYMPHOCYTIC INFILTRATION; MALE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; RAT; SUBCUTANEOUS TISSUE; ANGIOGENESIS; ANIMAL; AUGUST COPENHAGEN IRISH RAT; DIABETES MELLITUS, EXPERIMENTAL; LEWIS RAT; METABOLISM; MORTALITY; PHYSIOLOGY; VASCULARIZATION; WISTAR RAT;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; FIBROBLAST GROWTH FACTOR 2; GLUCOSE TOLERANCE TEST; GRAFT SURVIVAL; HEPARIN; INSULIN; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, INBRED ACI; RATS, INBRED LEW; RATS, WISTAR; SUBCUTANEOUS TISSUE;

EID: 84903158736     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12739     Document Type: Article

References (38)

1. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230-238.
2. Ryan EA, Paty BW, Senior PA, et al. Five year follow-up after clinical islet transplantation. Diabetes 2005; 54: 2060-2069.
3. Barton FB, Rickels MR, Alejandro R, et al. Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care 2012; 35: 1436-1445.
4. Hansson M, Madsen OD., Pluripotent stem cells, a potential source of beta-cells for diabetes therapy. Curr Opin Investig Drugs 2010; 11: 417-425.
5. Wagner RT, Lewis J, Cooney A, Chan L., Stem cell approaches for the treatment of type 1 diabetes mellitus. Transl Res 2010; 156: 169-179.
6. Aguayo-Mazzucato C, Bonner-Weir S., Stem cell therapy for type 1 diabetes mellitus. Nat Rev Endocrinol 2010; 6: 139-148.
7. Bouwens L, Houbracken I, Mfopou JK., The use of stem cells for pancreatic regeneration in diabetes mellitus. Nat Rev Endocrinol 2013; 9: 598-606.
8. Merani S, Toso C, Emamaullee J, Shapiro AM., Optimal implantation site for pancreatic islet transplantation. Br J Surg 2008; 95: 1449-1461.
9. van der Windt DJ, Echeverri GJ, Ijzermans JN, Cooper DK., The choice of anatomical site for islet transplantation. Cell Transplant 2008; 17: 1005-1014.
10. Ricordi C, Lacy PE, Sterbenz K, Davie JM., Low-temperature culture of human islets or in vivo treatment with L3T4 antibody produces a marked prolongation of islet human-to-mouse xenograft survival. Proc Natl Acad Sci USA 1987; 84: 8080-8084.
11. Sullivan FP, Ricordi C, Hauptfeld V, Lacy PE., Effect of low-temperature culture and site of transplantation on hamster islet xenograft survival (hamster to mouse). Transplantation 1987; 44: 465-468.
12. Kenyon NS, Strasser S, Alejandro R., Ultraviolet light immunomodulation of canine islets for prolongation of allograft survival. Diabetes 1990; 39: 305-311.
13. Deol HS, Tuch BE., Effects of ultraviolet B irradiation on fetal pig islet-like cell clusters. Xenotransplantation 1998; 5: 292-297.
14. Teramura Y, Iwata H., Bioartificial pancreas microencapsulation and conformal coating of islet of Langerhans. Adv Drug Deliv Rev 2010; 62: 827-840.
15. Kawakami Y, Iwata H, Gu YJ, et al. Successful subcutaneous pancreatic islet transplantation using an angiogenic growth factor-releasing device. Pancreas 2001; 23: 375-381.
16. Luan NM, Iwata H., Xenotransplantation of islets enclosed in agarose microcapsule carrying soluble complement receptor 1. Biomaterials 2012; 33: 8075-8081.
17. Luan NM, Teramura Y, Iwata H., Immobilization of the soluble domain of human complement receptor 1 on agarose-encapsulated islets for the prevention of complement activation. Biomaterials 2010; 31: 8847-8853.
18. Luan NM, Teramura Y, Iwata H., Layer-by-layer co-immobilization of soluble complement receptor 1 and heparin on islets. Biomaterials 2011; 32: 6487-6492.
19. Luan NM, Iwata H., Inhibition of instant blood-mediated inflammatory responses by co-immobilization of sCR1 and heparin on islets. Biomaterials 2013; 34: 5019-5024.
20. Hasegawa Y, Nakagawara G, Imamura Y, Iwata H, Ikada Y., Function and fate of agarose microcapsules containing allogeneic islets in rat recipients. Polymer Adv Tech 1998; 9: 794-798.
21. Kemp CB, Knight MJ, Scharp DW, Ballinger WF, Lacy PE., Effect of transplantation site on the results of pancreatic islet isografts in diabetic rats. Diabetologia 1973; 9: 486-491.
22. Juang JH, Hsu BR, Kuo CH., Islet transplantation at subcutaneous and intramuscular sites. Transplant Proc 2005; 37: 3479-3481.
23. Juang JH, Bonner-Weir S, Ogawa Y, Vacanti JP, Weir GC., Outcome of subcutaneous islet transplantation improved by polymer device. Transplantation 1996; 61: 1557-1561.
24. Kawakami Y, Iwata H, Gu Y, et al. Modified subcutaneous tissue with neovascularization is useful as the site for pancreatic islet transplantation. Cell Transplant 2000; 9: 729-732.
25. Gu Y, Tabata Y, Kawakami Y, et al. Development of a new method to induce angiogenesis at subcutaneous site of streptozotocin-induced diabetic rats for islet transplantation. Cell Transplant 2001; 10: 453-457.
26. Pileggi A, Molano RD, Ricordi C, et al. Reversal of diabetes by pancreatic islet transplantation into a subcutaneous, neovascularized device. Transplantation 2006; 81: 1318-1324.
27. Halberstadt CR, Williams D, Emerich D, et al. Subcutaneous transplantation of islets into streptozocin-induced diabetic rats. Cell Transplant 2005; 14: 595-605.
28. Bhang SH, Jung MJ, Shin JY, et al. Mutual effect of subcutaneously transplanted human adipose-derived stem cells and pancreatic islets within fibrin gel. Biomaterials 2013; 34: 7247-7256.
29. Barkai U, Weir GC, Colton CK, et al. Enhanced oxygen supply improves islet viability in a new bioartificial pancreas. Cell Transplant 2013; 22: 1463-1476.
30. Ludwig B, Rotem A, Schmid J, et al. Improvement of islet function in a bioartificial pancreas by enhanced oxygen supply and growth hormone releasing hormone agonist. Proc Natl Acad Sci USA 2012; 109: 5022-5027.
31. Perez-Basterrechea M, Briones RM, Alvarez-Viejo M, et al. Plasma-fibroblast gel as scaffold for islet transplantation. Tissue Eng Part A 2009; 15: 569-577.
32. Wang W, Gu Y, Tabata Y, et al. Reversal of diabetes in mice by xenotransplantation of a bioartificial pancreas in a prevascularized subcutaneous site. Transplantation 2002; 73: 122-129.
33. Wang W, Gu Y, Hori H, et al. Subcutaneous transplantation of macroencapsulated porcine pancreatic endocrine cells normalizes hyperglycemia in diabetic mice. Transplantation 2003; 76: 290-296.
34. Lacy PE, Hegre OD, Gerasimidi-Vazeou A, Gentile FT, Dionne KE., Maintenance of normoglycemia in diabetic mice by subcutaneous xenografts of encapsulated islets. Science 1991; 254: 1782-1784.
35. Dufrane D, Goebbels RM, Gianello P., Alginate macroencapsulation of pig islets allows correction of streptozotocin-induced diabetes in primates up to 6 months without immunosuppression. Transplantation 2010; 90: 1054-1062.
36. Wood KJ, Bushell A, Hester J., Regulatory immune cells in transplantation. Nat Rev Immunol 2012; 12: 417-430.
37. 3+ regulatory T lymphocytes. Nat Med 2008; 14: 88-92.
38. Ostrand-Rosenberg S, Sinha P., Myeloid-derived suppressor cells: Linking inflammation and cancer. J Immunol 2009; 182: 4499-4506.